Nanoparticulate carrier containing water-insoluble iodinated oil as a multifunctional contrast agent for computed tomography imaging.

Contrast-enhanced computed tomography (CT) imaging is a valuable and routine strategy for the clinical diagnosis of various diseases. However, all current CT contrast agents are liquids, so they flow through the blood vessels and disappear very quickly by extravasation. If it were possible to make a blood-compatible particulate contrast agent, we could highlight a particular tissue by either passive or active targeting. In this work, Pluronic F127 and a naturally iodinated compound, Lipiodol, were used to form radiopaque nanoreservoir structures. The resultant nanoparticles have a stable structure at high concentrations, sufficient X-ray absorption, a safety profile similar to or better than that of Iopromide, and a longer circulation time than commercial iodinated preparations. The utility of the resultant radiopaque nanoparticles as a contrast agent was tested using micro-SPECT/CT imaging in vivo. Together with the very good solubility of hydrophobic drugs (e.g., Taxol) in Lipiodol, these results suggest the possibility that these particulate structures and their bioconjugates could become functional CT contrast agents that could deliver therapeutic agents to a particular tissue.

[1]  H. El-Shall,et al.  Interaction of PLGA nanoparticles with human blood constituents. , 2005, Colloids and surfaces. B, Biointerfaces.

[2]  M. Ferrari Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[3]  Yuhan Lee,et al.  Oil-encapsulating PEO-PPO-PEO/PEG shell cross-linked nanocapsules for target-specific delivery of paclitaxel. , 2007, Biomacromolecules.

[4]  M. Yokoyama,et al.  Drug targeting with nano-sized carrier systems , 2005, Journal of Artificial Organs.

[5]  R. Duncan The dawning era of polymer therapeutics , 2003, Nature Reviews Drug Discovery.

[6]  R. Hicks,et al.  PET/CT: will it change the way that we use CT in cancer imaging? , 2006, Cancer imaging : the official publication of the International Cancer Imaging Society.

[7]  岩井 顕 Use of oily contrast medium for selective drug targeting to tumor : enhanced therapeutic effect and X-ray image , 1986 .

[8]  A. Kawashima,et al.  A new assay for lipiodol in a tumor using a combination of m-chloroperbenzoic acid-mediated oxidation and the iodo-starch reaction. , 2000, Cancer letters.

[9]  Jin Ho Jung,et al.  A Compact SPECT/CT System for Small Animal Imaging , 2006, IEEE Transactions on Nuclear Science.

[10]  H. Yoo,et al.  Cationic lipid emulsions containing heavy oils for the transfection of adherent cells. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[11]  Young Joo Kim,et al.  Lipiodol solution of a lipophilic agent, (188)Re-TDD, for the treatment of liver cancer. , 2001, Nuclear medicine and biology.

[12]  Jan Grimm,et al.  An X-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles , 2006, Nature materials.

[13]  T. Nishimura,et al.  Spontaneous healing of chyle leakage after lymphangiography. , 2005, The British journal of radiology.

[14]  J. Brink Use of high concentration contrast media (HCCM): principles and rationale--body CT. , 2003, European journal of radiology.

[15]  Alexander V Kabanov,et al.  Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[16]  Rodney J Hicks,et al.  Imaging in the diagnosis and treatment of non‐small cell lung cancer , 2007, Respirology.

[17]  E. Bacon,et al.  Pulmonary delivery of nanoparticles of insoluble, iodinated CT X-ray contrast agents to lung draining lymph nodes in dogs. , 1998, Journal of pharmaceutical sciences.